Coherus Biosciences Inc (CHRS) concluded trading on Thursday at a closing price of $1.50, with 3.83 million shares of worth about $5.75 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -15.73% during that period and on December 12, 2024 the price saw a loss of about -9.09%. Currently the company’s common shares owned by public are about 115.21M shares, out of which, 110.58M shares are available for trading.
Stock saw a price change of -0.66% in past 5 days and over the past one month there was a price change of 82.15%. Year-to-date (YTD), CHRS shares are showing a performance of -54.95% which decreased to -28.23% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.66 but also hit the highest price of $3.70 during that period. The average intraday trading volume for Coherus Biosciences Inc shares is 5.23 million. The stock is currently trading 16.10% above its 20-day simple moving average (SMA20), while that difference is up 45.90% for SMA50 and it goes to -5.22% lower than SMA200.
Coherus Biosciences Inc (NASDAQ: CHRS) currently have 115.21M outstanding shares and institutions hold larger chunk of about 66.08% of that.
The stock has a current market capitalization of $172.82M and its 3Y-monthly beta is at 0.85. It has posted earnings per share of -$0.10 in the same period. It has Quick Ratio of 1.09. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CHRS, volatility over the week remained 11.82% while standing at 15.60% over the month.
Stock’s fiscal year EPS is expected to rise by 113.96% while it is estimated to decrease by -222.35% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by UBS on August 16, 2024 offering a Neutral rating for the stock and assigned a target price range of between $4 and $1.50 to it. Coverage by Robert W. Baird stated Coherus Biosciences Inc (CHRS) stock as an Outperform in their note to investors on November 17, 2023, suggesting a price target of $11 for the stock. On November 08, 2023, Maxim Group Downgrade their recommendations, while on July 24, 2023, Citigroup Initiated their ratings for the stock with a price target of $12. Stock get a Buy rating from Truist on May 01, 2023.
